Jesse Gelsinger had ornithine transcarbamylase (OTC) deficiency, which is a rare genetic disease in the liver that hinders the breaking down of ammonia in the body. When he was eighteen, he volunteered for gene therapy in hopes of curing his disease. However, little did he and the outside world knew that the scientists studying gene therapy hid some terrible news. Before the testing on Jesse, the researchers of University of Pennsylvania injected a virus also known as adenoviral vector into two baboons. The researchers believed that when adenoviral vector is injected to the body of the subject, it should not cause any defects to the organs but instead help replace the defective chromosome. Despite that, the two baboons died. The researchers failed to report this incident to the Food and Drug Association (FDA). Other than that, they also failed to report that two patients suffered from terrible side effects which would have stopped the continuation of gene
Jesse Gelsinger had ornithine transcarbamylase (OTC) deficiency, which is a rare genetic disease in the liver that hinders the breaking down of ammonia in the body. When he was eighteen, he volunteered for gene therapy in hopes of curing his disease. However, little did he and the outside world knew that the scientists studying gene therapy hid some terrible news. Before the testing on Jesse, the researchers of University of Pennsylvania injected a virus also known as adenoviral vector into two baboons. The researchers believed that when adenoviral vector is injected to the body of the subject, it should not cause any defects to the organs but instead help replace the defective chromosome. Despite that, the two baboons died. The researchers failed to report this incident to the Food and Drug Association (FDA). Other than that, they also failed to report that two patients suffered from terrible side effects which would have stopped the continuation of gene